---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-076184"
form_type: "8-K"
ticker: "ORKA"
cik: "0000907654"
company_name: "Oruka Therapeutics, Inc."
filed_at: "2024-09-05T23:59:59+00:00"
generated_at: "2026-05-31T06:22:09.886941+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# ARCA completes reverse merger with Oruka; combined entity renamed Oruka Therapeutics (ORKA)

## Summary
- Merger closed: ARCA (shell) merges with private Oruka; Oruka shareholders own ~97.6% of combined company.
- Pre-closing financing raised ~$275M gross from new & existing investors; includes $25M convertible note.
- Special cash dividend of ~$23.4M ($1.613/share) paid to ARCA stockholders on Aug 28, 2024.
- Reverse stock split (1-for-12) effective Sept 3, 2024; post-split common shares outstanding: ~29.4M.
- Combined company changes name to Oruka Therapeutics, Inc. (ORKA) and begins trading on Nasdaq.

## SEC filing metadata
- accession: 0001213900-24-076184
- form_type: 8-K
- ticker: ORKA
- cik: 0000907654
- company_name: Oruka Therapeutics, Inc.
- filed_at: 2024-09-05T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 5.07, 1.01, 2.01, 5.02, 9.01, 2.02, 3.03, 4.01, 5.01, 5.03, 5.05, 5.06, 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/907654/000121390024076184/0001213900-24-076184-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/907654/000121390024076184/ea0213193-8k_orukathera.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-076184
- JSON: https://secwatch.observer/filing/0001213900-24-076184.json
- Plain text: https://secwatch.observer/filing/0001213900-24-076184.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.